

July 24, 2020

Listing Department

BSE LIMITED

P J Towers, Dalal Street, Fort,
Mumbai – 400 001

Code: 532 321

Listing Department

NATIONAL STOCK EXCHANGE OF INDIA LIMITED

Exchange Plaza, Bandra Kurla Complex,
Bandra (E),
Mumbai – 400 051

Code: CADILAHC

Re.: Details on Covid-19 impact

Ref.: SEBI Circular dated May 20, 2020

Dear Sir/Madam,


Please find enclosed the prescribed details on Covid-19 impact on the Company as per the SEBI Circular dated May 20, 2020.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking you,

Yours faithfully,

For, **CADILA HEALTHCARE LIMITED**


DHAVAL N. SONI
COMPANY SECRETARY



Encl.: As above

Prescribed details as per SEBI Circular dated May 20, 2020:

Sr. No.	Disclosure required	Response
1.	Impact of the Covid-19 pandemic on the business	<p>The World Health Organisation (“WHO”) declared Covid-19 to be a global pandemic in March 2020. Government of India declared the lockdown from last week of March, 2020, which continued for the whole of April, 2020 and major part of May, 2020. In some of the states, the lock down continued in June, 2020 also.</p> <p>Covid-19 pandemic has impacted the business operations across various sectors of the global economy with restrictions on movement of people and goods.</p> <p>We operate in manufacturing and selling of pharmaceutical products, which are classified as essential commodities and hence our operations continued to be run with fewer challenges on people movement and supply chain.</p> <p>As per the current assessment of the situation based on the internal and external information available till date, we believe that the impact of Covid-19 on our business would not be significant.</p>



Sr. No.	Disclosure required	Response
2.	Ability to maintain operations including the factories / units / office spaces functioning and closed down	<p>At present, our manufacturing facilities are operating at a reasonable capacity utilization and we are ensuring that our medicines are available to patients without interruptions. Wherever required we have also worked with the local authorities to get the support in terms of smooth operations of manufacturing facilities. We have strengthened our supply chain with a specific focus on helping MSME parties in surviving the difficult times.</p> <p>We have implemented several initiatives across our manufacturing and other business locations including allowing work from homes, social distancing at work places and proper sanitization of work places etc. for ensuring safety of our employees and continuity of our business operations with minimal disruption.</p>
3.	Schedule, if any, for restarting the operations	<p>Most of our manufacturing facilities at various locations were already operating during the lockdown situation.</p> <p>Based on the directives from the Central and State Government and local bodies, we have also resumed operations at our corporate office with limited workforce.</p>



Sr. No.	Disclosure required	Response
4.	Steps taken to ensure smooth functioning of operations	<p>Apart from following all protocols and guidelines issued by global health organizations like WHO for Covid-19, we have come out with our own advisory for the employees for safety of our employees.</p> <p>Our focus is on ensuring the safety of our employees and all other stakeholders while we continue to work both on treatment and prevention of the pandemic. The saving of lives and protecting livelihood both are of utmost importance to us.</p> <p>In Zydus, we have created a group of senior management team to monitor the events happening in the external environment and take suitable preventive and corrective measures to ensure continued safety of employees. The team has prepared a business continuity plan, disaster management plan and also established a liquidity management office.</p> <p>We would also like to mention that we have been doing whatever possible for the country in terms of fight against Covid-19. This includes, amongst others, supplying Hydroxychloroquine Sulphate tablets to the Govt. of India and other customers across several countries at very reasonable prices, manufacturing Covid testing kits for ICMR, partnering with Gilead Sciences Inc. for manufacturing of Remdesivir for India market, exploring the biologics route to treat the disease with our long-acting biological therapy Pegylated Interferon alpha-2b and working on development of a vaccine for Covid-19 virus.</p>



Sr. No.	Disclosure required	Response
5.	Estimation of the future impact of Covid-19 on its operations	<p>As per our current assessment of the situation based on the internal and external information available till date, we believe the future impact Covid-19 on our business operations would not be significant.</p> <p>The actual impact of the global health pandemic may be different from that which has been estimated by us, as Covid-19 pandemic evolves in India and globally.</p> <p>We are closely monitoring the situation and its impact on business operations, financial, employees, customers, vendors and business partners.</p> <p>We also find certain near-term and mid-term opportunities including treatment medicines and vaccines. Our India branded formulation business is somewhat affected due to lockdown situation and we remain cautiously optimistic about next 2 quarters of the Financial Year 2020-2021. Meanwhile, we are also finding newer ways of managing the business and have been working on the possibilities of using digital technology. Our focus on research and innovations remains intact and we wish to live by our slogan of "Dedicated to Life".</p>



Sr. No.	Disclosure required	Response
6.	<p>Details of impact of Covid-19 on listed entity's -</p> <ul style="list-style-type: none"> • capital and financial resources; • profitability; • liquidity position; • ability to service debt and other financing arrangements; • assets; • internal financial reporting and control; • supply chain • demand for its products / services 	<p>As mentioned earlier, according to our current assessment of the situation based on the internal and external information available till date, we believe that the impact of Covid-19 on our business, demand for our products and supply chain, assets, capital and financial resources, ability to service debt and other financing arrangements, internal financial controls, profitability and liquidity, both present and future, would not be significant.</p>
7.	<p>Existing contracts / agreements where non-fulfilment of the obligations by any party will have significant impact on the listed entity's business</p>	<p>No significant impact of such non-fulfilment of the obligations by any party on our business is expected.</p>

For, **CADILA HEALTHCARE LIMITED**

Dhaval N. Soni
DHAVAL N. SONI
COMPANY SECRETARY

